AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|October 13, 2009
Economist Award for Bioscience Innovation Announced
13 October
Advertisement
J. Craig Venter has won this year's Economist Innovation Award for Bioscience. Dr Venter, president of the J. Craig Venter Institute (JCVI)(
Commenting on his award, Dr Venter said: "We are now in a world 100% dependent on scientific innovation. Innovation is the key driver for success, especially in challenging economic times."
The award will be presented at a ceremony at London's Science museum on October 29th. The Economist's Innovation Summit, focusing on the interface between innovation and business, will take place the following day.
For more information on the winner and the award,
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
5